{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T11:04:57Z","timestamp":1788174297599,"version":"build-2803163510"},"reference-count":107,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100009227","name":"Department of Medicine, University of Toronto","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009227","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","onlinecjc.ca","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Cardiology"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.cjca.2020.11.014","type":"journal-article","created":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T19:58:59Z","timestamp":1606852739000},"page":"595-608","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["How Diabetes and Heart Failure Modulate Each Other and Condition Management"],"prefix":"10.1016","volume":"37","author":[{"given":"Varinder Kaur","family":"Randhawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Savita","family":"Dhanvantari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1031-3137","authenticated-orcid":false,"given":"Kim A.","family":"Connelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 1","key":"10.1016\/j.cjca.2020.11.014_bib2","first-page":"S1","article-title":"Diabetes Canada 2018 clinical practice guidelines for the prevention and management of diabetes in Canada","volume":"42","year":"2018","journal-title":"Can J Diabetes"},{"issue":"Suppl 1","key":"10.1016\/j.cjca.2020.11.014_bib3","doi-asserted-by":"crossref","first-page":"S88","DOI":"10.1016\/j.jcjd.2017.10.034","article-title":"Diabetes Canada 2018 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada: pharmacologic glycemic management of type 2 diabetes in adults","volume":"42","author":"Lipsombe","year":"2018","journal-title":"Can J Diabetes"},{"key":"10.1016\/j.cjca.2020.11.014_bib4","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s12872-018-0815-3","article-title":"Cost-of-illness studies in heart failure: a systematic review 2004-2016","volume":"18","author":"Lesyuk","year":"2018","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.cjca.2020.11.014_bib5","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/j.jacc.2018.01.047","article-title":"Prevalent and incident heart failure in cardiovascular outcome trials of patients with type 2 diabetes","volume":"71","author":"Greene","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2020.11.014_bib6","doi-asserted-by":"crossref","first-page":"773","DOI":"10.2337\/db09-9028","article-title":"Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus","volume":"58","author":"Defronzo","year":"2009","journal-title":"Diabetes"},{"key":"10.1016\/j.cjca.2020.11.014_bib7","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1161\/CIRCRESAHA.117.311586","article-title":"Diabetic cardiomyopathy: an update of mechanisms contributing to this clinical entity","volume":"122","author":"Jia","year":"2018","journal-title":"Circ Res"},{"key":"10.1016\/j.cjca.2020.11.014_bib8","doi-asserted-by":"crossref","first-page":"3264","DOI":"10.3390\/ijms20133264","article-title":"Molecular dysfunction and phenotypic derangement in diabetic cardiomyopathy","volume":"20","author":"Evangelista","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.cjca.2020.11.014_bib9","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1128\/MCB.01110-06","article-title":"Essential role of insulin and insulin-like growth factor 1 receptor signaling in cardiac development and function","volume":"27","author":"Laustsen","year":"2007","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.cjca.2020.11.014_bib10","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/j.1440-1681.2012.05738.x","article-title":"Myocardial insulin resistance, metabolic stress and autophagy in diabetes","volume":"40","author":"Mellor","year":"2013","journal-title":"Clin Experiment Pharmacol Physiol"},{"key":"10.1016\/j.cjca.2020.11.014_bib11","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1161\/01.RES.87.12.1123","article-title":"Myocardial cell death in human diabetes","volume":"87","author":"Frustaci","year":"2000","journal-title":"Circ Res"},{"key":"10.1016\/j.cjca.2020.11.014_bib12","first-page":"434","article-title":"Macro- and microvascular endothelial dysfunction in diabetes","volume":"9","author":"Shi","year":"2017","journal-title":"J\u00a0Diabetes"},{"key":"10.1016\/j.cjca.2020.11.014_bib13","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1093\/eurheartj\/ehv134","article-title":"Clinical diabetic cardiomyopathy: a two-faced disease with restrictive and dilated phenotypes","volume":"36","author":"Seferovic","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2020.11.014_bib14","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/0002-9149(72)90595-4","article-title":"New type of cardiomyopathy associated with diabetic glomerulosclerosis","volume":"30","author":"Rubler","year":"1972","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cjca.2020.11.014_bib15","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ijcard.2018.04.001","article-title":"Non-cardiac comorbidities in heart failure with reduced, mid-range and preserved ejection fraction","volume":"271","author":"Streng","year":"2018","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.cjca.2020.11.014_bib16","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.hfc.2012.06.005","article-title":"Insulin resistance and heart failure: molecular mechanisms","volume":"8","author":"Aroor","year":"2012","journal-title":"Heart Fail Clin"},{"key":"10.1016\/j.cjca.2020.11.014_bib17","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.2337\/diacare.24.9.1614","article-title":"Congestive heart failure in type 2 diabetes: prevalence, incidence, and risk factors","volume":"24","author":"Nichols","year":"2001","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cjca.2020.11.014_bib18","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S2213-8587(14)70219-0","article-title":"Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1.9 million people","volume":"3","author":"Shah","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.cjca.2020.11.014_bib19","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s12933-019-0883-4","article-title":"Heart failure and the prognostic impact and incidence of new-onset of diabetes mellitus: a nationwide cohort study","volume":"18","author":"Zareini","year":"2019","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.cjca.2020.11.014_bib20","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1001\/jama.1979.03290450033020","article-title":"Diabetes and cardiovascular disease: the Framingham study","volume":"241","author":"Kannel","year":"1979","journal-title":"JAMA"},{"key":"10.1016\/j.cjca.2020.11.014_bib21","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ahj.2016.07.025","article-title":"Temporal trends and factors associated with diabetes mellitus among patients hospitalized with heart failure: findings from Get With The Guidelines heart failure registry","volume":"182","author":"Echouffo-Tcheugui","year":"2016","journal-title":"Am Heart J"},{"key":"10.1016\/j.cjca.2020.11.014_bib22","doi-asserted-by":"crossref","first-page":"699","DOI":"10.2337\/diacare.27.3.699","article-title":"Heart failure prevalence, incidence, and mortality in the elderly with diabetes","volume":"27","author":"Bertoni","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cjca.2020.11.014_bib23","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0234260","article-title":"The role of diabetes in cardiomyopathies of different etiologies: characteristics and 1-year follow-up results of the EVITA-HF registry","volume":"15","author":"Meindl","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.cjca.2020.11.014_bib24","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.2337\/dc19-0587","article-title":"Machine learning to predict the risk of incident heart failure hospitalization among patients with diabetes: the WATCH-DM Risk Score","volume":"42","author":"Segar","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cjca.2020.11.014_bib25","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1016\/j.jacc.2006.06.078","article-title":"Myocardial glucose transport and utilization in patients with type 2 diabetes mellitus, left ventricular dysfunction, and coronary artery disease","volume":"48","author":"Dutka","year":"2006","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2020.11.014_bib26","doi-asserted-by":"crossref","first-page":"084","DOI":"10.2337\/dc10-0286","article-title":"Diabetes, glycemic control, and new-onset heart failure in patients with stable coronary artery disease: data from the heart and soul study","volume":"33","author":"van Melle","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cjca.2020.11.014_bib27","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1161\/CIRCOUTCOMES.111.962522","article-title":"Long-term effects of incident diabetes mellitus on cardiovascular outcomes in people treated for hypertension: the ALLHAT diabetes extension study","volume":"5","author":"Barzilay","year":"2012","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.cjca.2020.11.014_bib28","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1001\/archinternmed.2009.60","article-title":"ALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analyses","volume":"169","author":"Wright","year":"2009","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.cjca.2020.11.014_bib29","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S0002-9343(99)00126-6","article-title":"Risk factors for heart failure in the elderly: a prospective community-based study","volume":"106","author":"Chen","year":"1999","journal-title":"Am J Med"},{"key":"10.1016\/j.cjca.2020.11.014_bib30","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.2337\/dc17-2583","article-title":"Risk of incident heart failure in patients with diabetes and asymptomatic left ventricular systolic dysfunction","volume":"41","author":"R\u00f8rth","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cjca.2020.11.014_bib31","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s10741-018-9685-0","article-title":"The heart failure burden of type 2 diabetes mellitus: a review of pathophysiology and interventions","volume":"23","author":"Ofstad","year":"2018","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.cjca.2020.11.014_bib32","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1136\/bmj.321.7258.405","article-title":"Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study","volume":"321","author":"Stratton","year":"2000","journal-title":"BMJ"},{"key":"10.1016\/j.cjca.2020.11.014_bib33","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1161\/CIRCULATIONAHA.106.661405","article-title":"Glucose levels predict hospitalization for congestive heart failure in patients at high cardiovascular risk","volume":"115","author":"Held","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2020.11.014_bib34","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1001\/archinte.168.15.1699","volume":"168","author":"Gerstein","year":"2008","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.cjca.2020.11.014_bib35","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.annepidem.2003.09.004","article-title":"Excess mortality related to diabetes mellitus in elderly Medicare beneficiaries","volume":"14","author":"Bertoni","year":"2004","journal-title":"Ann Epidemiol"},{"key":"10.1016\/j.cjca.2020.11.014_bib36","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1007\/s00125-012-2579-0","article-title":"High prevalence of previously unknown heart failure and left ventricular dysfunction in patients with type 2 diabetes","volume":"55","author":"Boonman-de Winter","year":"2012","journal-title":"Diabetologia"},{"key":"10.1016\/j.cjca.2020.11.014_bib37","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.diabres.2013.07.004","article-title":"The increasing detection of asymptomatic left ventricular dysfunction in patients with type 2 diabetes mellitus without overt cardiac disease: data from the SHORTWAVE study","volume":"101","author":"Faden","year":"2013","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.cjca.2020.11.014_bib38","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1161\/CIRCULATIONAHA.114.014796","article-title":"Impact of diabetes mellitus on hospitalization for heart failure, cardiovascular events, and death: outcomes at 4 years from the Reduction of Atherothrombosis for Continued Health (REACH) registry","volume":"132","author":"Cavender","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2020.11.014_bib39","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1093\/eurheartj\/ehn153","article-title":"CHARM Investigators. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme","volume":"29","author":"MacDonald","year":"2008","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2020.11.014_bib40","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.jacc.2018.11.033","article-title":"Heart failure with preserved rjection fraction and diabetes: JACC State-of-the-Art Review","volume":"73","author":"McHugh","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2020.11.014_bib41","first-page":"632","article-title":"Heart failure with preserved ejection fraction in diabetes: mechanisms and management","volume":"34","author":"Meagher","year":"2018","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjca.2020.11.014_bib42","doi-asserted-by":"crossref","first-page":"150","DOI":"10.2337\/dc17-0755","article-title":"The prognostic significance of diabetes and microvascular complications in patients with heart failure with preserved ejection fraction","volume":"41","author":"Sandesara","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cjca.2020.11.014_bib43","first-page":"1342","article-title":"2017 Comprehensive update of the Canadian Cardiovascular Society guidelines for the management of heart failure","volume":"33","author":"Ezekowitz","year":"2017","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjca.2020.11.014_bib44","first-page":"159","article-title":"CCS\/CHFS heart failure guidelines: clinical trial update on functional mitral regurgitation, SGLT2 inhibitors, ARNI in HFpEF, and tafamidis in amyloidosis","volume":"36","author":"O'Meara","year":"2020","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjca.2020.11.014_bib45","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.2337\/dc07-0717","article-title":"Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08)","volume":"30","author":"Erdmann","year":"2007","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cjca.2020.11.014_bib46","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1093\/eurheartj\/ehp604","article-title":"Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial","volume":"31","author":"Komajda","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2020.11.014_bib47","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.coph.2006.06.009","article-title":"PPARalpha and PPARgamma dual agonists for the treatment of type 2 diabetes and the metabolic syndrome","volume":"6","author":"Fievet","year":"2006","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.cjca.2020.11.014_bib48","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.ahj.2011.07.030","article-title":"Intensive glycemic control has no impact on the risk of heart failure in type 2 diabetic patients: evidence from a 37,229 patient meta-analysis","volume":"162","author":"Castagno","year":"2011","journal-title":"Am Heart J"},{"key":"10.1016\/j.cjca.2020.11.014_bib49","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0735-1097(00)00717-8","article-title":"Effects of insulin-glucose infusion on left ventricular function at rest and during dynamic exercise in healthy subjects and noninsulin dependent diabetic patients: a radionuclide ventriculographic study","volume":"36","author":"Sasso","year":"2000","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2020.11.014_bib50","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa1203858","article-title":"Basal insulin and cardiovascular and other outcomes in dysglycemia","volume":"367","author":"Gerstein","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2020.11.014_bib51","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1056\/NEJMoa1600869","article-title":"Bariatric surgery versus intensive medical therapy for diabetes: 5-year outcomes","volume":"376","author":"Schauer","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2020.11.014_bib52","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1001\/jama.2018.3024","article-title":"Association between use of sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 agonists, and dipeptidyl peptidase 4 inhibitors with all-cause mortality in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"319","author":"Zheng","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.cjca.2020.11.014_bib53","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.cardfail.2015.12.007","article-title":"Response to exercise training and outcomes in patients with heart failure and diabetes mellitus: insights from the HF-ACTION trial","volume":"22","author":"Banks","year":"2016","journal-title":"J\u00a0Card Fail"},{"key":"10.1016\/j.cjca.2020.11.014_bib54","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2014-000163","article-title":"Exercise-based rehabilitation for heart failure: systematic review and meta-analysis","volume":"2","author":"Sagar","year":"2015","journal-title":"Open Heart"},{"key":"10.1016\/j.cjca.2020.11.014_bib55","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1089\/met.2018.0092","article-title":"Benefits of 1-year lifestyle modification program on exercise capacity and diastolic function among coronary artery disease men with and without type 2 diabetes","volume":"17","author":"Pich\u00e9","year":"2019","journal-title":"Metab Syndr Relat Disord"},{"key":"10.1016\/j.cjca.2020.11.014_bib56","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1161\/CIRCRESAHA.118.311371","article-title":"Heart failure in type 2 diabetes mellitus","volume":"124","author":"Kenny","year":"2019","journal-title":"Circ Res"},{"key":"10.1016\/j.cjca.2020.11.014_bib57","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1161\/CIRCULATIONAHA.119.040144","article-title":"Metformin use and clinical outcomes among patients with diabetes mellitus with or without heart failure or kidney dysfunction: observations from the SAVOR-TIMI 53 trial","volume":"140","author":"Bergmark","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2020.11.014_bib58","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1001\/archinternmed.2010.409","article-title":"Metformin use and mortality among patients with diabetes and atherothrombosis","volume":"170","author":"Roussel","year":"2010","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.cjca.2020.11.014_bib59","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1161\/CIRCHEARTFAILURE.112.000162","article-title":"Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure: systematic review of observational studies involving 34,000 patients","volume":"6","author":"Eurich","year":"2013","journal-title":"Circ Heart Fail"},{"issue":"suppl 1","key":"10.1016\/j.cjca.2020.11.014_bib60","article-title":"GLP-1 receptor agonists and heart failure in diabetes","volume":"43","author":"Scheen","year":"2017","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.cjca.2020.11.014_bib61","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s12933-016-0421-6","article-title":"Rationale and design of the randomised controlled trial to assess the impact of liraglutide on cardiac function and structure in young adults with type 2 diabetes (the LYDIA study)","volume":"15","author":"Htike","year":"2016","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.cjca.2020.11.014_bib62","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1001\/jama.2016.10260","article-title":"NHLBI Heart Failure Clinical Research Network. Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial","volume":"316","author":"Margulies","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.cjca.2020.11.014_bib63","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1161\/CIRCRESAHA.117.311588","article-title":"Cardiovascular effects of new oral glucose-lowering agents: DPP-4 and SGLT-2 inhibitors","volume":"122","author":"Scheen","year":"2018","journal-title":"Circ Res"},{"key":"10.1016\/j.cjca.2020.11.014_bib64","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1161\/CIRCULATIONAHA.118.038352","article-title":"Linagliptin effects on heart failure and related outcomes in individuals with type 2 diabetes mellitus at high cardiovascular and renal risk in CARMELINA","volume":"139","author":"McGuire","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2020.11.014_bib65","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jchf.2017.08.004","article-title":"VIVIDD Trial Committees and Investigators. Effects of vildagliptin on ventricular function in patients with type 2 diabetes mellitus and heart failure: a randomized placebo-controlled trial","volume":"6","author":"McMurray","year":"2018","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.cjca.2020.11.014_bib66","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s12020-014-0175-4","article-title":"Effects of incretin-based therapy in patients with heart failure and myocardial infarction","volume":"47","author":"Mikhail","year":"2014","journal-title":"Endocrine"},{"key":"10.1016\/j.cjca.2020.11.014_bib67","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1001\/jama.2019.2942","article-title":"Effect of Additional oral semaglutide vs sitagliptin on glycated hemoglobin in adults with type 2 diabetes uncontrolled with metformin alone or with sulfonylurea: the PIONEER 3 randomized clinical trial","volume":"321","author":"Rosenstock","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.cjca.2020.11.014_bib68","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1161\/CIRCULATIONAHA.114.010389","article-title":"SAVOR-TIMI 53 Steering Committee and Investigators. Heart Failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial","volume":"130","author":"Scirica","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2020.11.014_bib69","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1111\/dom.14023","article-title":"A\u00a0randomized, open-label, active comparator trial assessing the effects of 26 weeks of liraglutide or sitagliptin on cardiovascular function in young obese adults with type 2 diabetes","volume":"22","author":"Webb","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.cjca.2020.11.014_bib70","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1016\/S0140-6736(14)62225-X","article-title":"Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial","volume":"385","author":"Zannad","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2020.11.014_bib71","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.3389\/fphys.2018.01622","article-title":"Saxagliptin but not sitagliptin inhibits CaMKII and PKC via DPP9 inhibition in cardiomyocytes","volume":"9","author":"Koyani","year":"2018","journal-title":"Front Physiol"},{"key":"10.1016\/j.cjca.2020.11.014_bib72","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1161\/CIRCULATIONAHA.119.040514","article-title":"The serendipitous story of SGLT2 inhibitors in heart failure","volume":"139","author":"Verma","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2020.11.014_bib73","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2020.11.014_bib74","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","article-title":"SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"393","author":"Zelniker","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2020.11.014_bib75","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1161\/CIRCULATIONAHA.119.040057","article-title":"Effects of canagliflozin on heart failure outcomes associated with preserved and reduced ejection fraction in type 2 diabetes mellitus","volume":"139","author":"Figtree","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2020.11.014_bib76","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1161\/CIRCULATIONAHA.119.040130","article-title":"Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus","volume":"139","author":"Kato","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2020.11.014_bib77","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2020.11.014_bib78","article-title":"The VERTIS CV trial: cardiovascular outcomes following ertugliflozin treatment in patients with type 2 diabetes mellitus and atherosclerotic cardiovascular disease","author":"Pratley","year":"2020","journal-title":"American Diabetes Association (ADA) Virtual 88th Scientific Sessions"},{"key":"10.1016\/j.cjca.2020.11.014_bib79","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1080\/17512433.2019.1588110","article-title":"Heart failure hospitalization with SGLT-2 inhibitors: a systematic review and meta-analysis of randomized controlled and observational studies","volume":"12","author":"Singh","year":"2019","journal-title":"Exp Rev Clin Pharmacol"},{"key":"10.1016\/j.cjca.2020.11.014_bib80","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000018245","article-title":"Effects of SGLT2 inhibitors on cardiovascular outcomes and mortality in type 2 diabetes: a meta-analysis","volume":"98","author":"Zou","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.cjca.2020.11.014_bib81","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1161\/CIRCULATIONAHA.119.042375","article-title":"Effect of empagliflozin on left ventricular mass in patients with type 2 diabetes mellitus and coronary artery disease: the EMPA-HEART CardioLink-6 randomized clinical trial","volume":"140","author":"Verma","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2020.11.014_bib82","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.2337\/dc19-2187","article-title":"Dapagliflozin versus placebo on left ventricular remodeling in patients with diabetes and heart failure: the REFORM trial","volume":"43","author":"Singh","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cjca.2020.11.014_bib83","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1093\/eurheartj\/ehaa943","article-title":"Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes","volume":"42","author":"Abraham","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2020.11.014_bib84","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1161\/CIRCULATIONAHA.120.051122","article-title":"Two tales: one story. EMPEROR-Reduced and DAPA-HF","volume":"142","author":"Verma","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2020.11.014_bib85","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2020.11.014_bib86","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S0140-6736(20)31824-9","article-title":"SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials","volume":"396","author":"Zannad","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2020.11.014_bib87","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"for the DAPA-CKD Trial Committees and Investigators. Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2020.11.014_bib88","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1161\/CIRCULATIONAHA.120.051783","article-title":"Effect of empagliflozin on the clinical stability of patients with heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial","volume":"143","author":"Packer","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2020.11.014_bib89","doi-asserted-by":"crossref","first-page":"4243","DOI":"10.1093\/eurheartj\/ehy596","article-title":"Heart failure and diabetes: metabolic alterations and therapeutic interventions: a state-of-the-art review from the Translational Research Committee of the Heart Failure Association-European Society of Cardiology","volume":"39","author":"Maack","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2020.11.014_bib90","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1093\/eurheartj\/ehaa183","article-title":"on behalf of the DAPA-HF Investigators and Committees, Effects of dapagliflozin in DAPA-HF according to background heart failure therapy. Effects of dapagliflozin in DAPA-HF according to background heart failure therapy","volume":"41","author":"Docherty","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2020.11.014_bib91","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1002\/ejhf.1170","article-title":"Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology","volume":"20","author":"Seferovi\u0107","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cjca.2020.11.014_bib92","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ahj.2018.07.002","article-title":"A\u00a0comparison of the effects of selective and non-selective mineralocorticoid antagonism on glucose homeostasis of heart failure patients with glucose intolerance or type II diabetes: a randomized controlled double-blind trial","volume":"204","author":"Korol","year":"2018","journal-title":"Am Heart J"},{"key":"10.1016\/j.cjca.2020.11.014_bib93","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.ahj.2010.04.024","article-title":"Effect of eplerenone versus spironolactone on cortisol and hemoglobin A(1)(c) levels in patients with chronic heart failure","volume":"160","author":"Yamaji","year":"2010","journal-title":"Am Heart J"},{"key":"10.1016\/j.cjca.2020.11.014_bib94","doi-asserted-by":"crossref","first-page":"915","DOI":"10.2337\/dc08-1709","article-title":"Predictors of development of diabetes in patients with chronic heart failure in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) program","volume":"32","author":"Preiss","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cjca.2020.11.014_bib95","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.ijcard.2013.12.039","article-title":"Spironolactone, not furosemide, improved insulin resistance in patients with chronic heart failure","volume":"171","author":"Ogino","year":"2014","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.cjca.2020.11.014_bib96","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.cardfail.2012.03.002","article-title":"Hypo- and hyperglycemia predict outcome in patients with left ventricular dysfunction after acute myocardial infarction: data from EPHESUS","volume":"18","author":"Ukena","year":"2012","journal-title":"J\u00a0Card Fail"},{"key":"10.1016\/j.cjca.2020.11.014_bib97","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1093\/eurjhf\/hfs067","article-title":"Eplerenone and new-onset diabetes in patients with mild heart failure: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF)","volume":"14","author":"Preiss","year":"2012","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cjca.2020.11.014_bib98","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/cpt.455","article-title":"Improved insulin sensitivity with angiotensin receptor neprilysin inhibition in individuals with obesity and hypertension","volume":"101","author":"Jordan","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.cjca.2020.11.014_bib99","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.biopha.2017.04.024","article-title":"Neprilysin inhibitors: a new hope to halt the diabetic cardiovascular and renal complications?","volume":"90","author":"Malek","year":"2017","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.cjca.2020.11.014_bib100","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1007\/s00125-019-4889-y","article-title":"Neprilysin inhibition: a new therapeutic option for type 2 diabetes?","volume":"62","author":"Esser","year":"2019","journal-title":"Diabetologia"},{"key":"10.1016\/j.cjca.2020.11.014_bib101","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1002\/ejhf.1342","article-title":"Effects of sacubitril\/valsartan on neprilysin targets and the metabolism of natriuretic peptides in chronic heart failure: a mechanistic clinical study","volume":"21","author":"Nougu\u00e9","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cjca.2020.11.014_bib102","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S2213-8587(18)30100-1","article-title":"Effect of neprilysin inhibition on renal function in patients with type 2 diabetes and chronic heart failure who are receiving target doses of inhibitors of the renin-angiotensin system: a secondary analysis of the PARADIGM-HF trial","volume":"6","author":"Packer","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.cjca.2020.11.014_bib103","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.115.002560","article-title":"Risk related to pre-diabetes mellitus and diabetes mellitus in heart failure with reduced ejection fraction: insights from prospective comparison of ARNI with ACEI to determine impact on clobal mortality and morbidity in heart failure trial","volume":"9","author":"Kristensen","year":"2016","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.cjca.2020.11.014_bib104","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S2213-8587(17)30087-6","article-title":"Effect of sacubitril\/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial","volume":"5","author":"Seferovic","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.cjca.2020.11.014_bib105","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2020.11.014_bib106","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.amjcard.2018.11.022","article-title":"Comparison of outcomes in patients with diabetes mellitus treated with versus without insulin+heart failure with preserved left ventricular ejection fraction (from the TOPCAT study)","volume":"123","author":"Huynh","year":"2019","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cjca.2020.11.014_bib107","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S0140-6736(10)61198-1","article-title":"on behalf of the SHIFT Investigators. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study","volume":"376","author":"Swedberg","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2020.11.014_bib108","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1002\/clc.23261","article-title":"Eplerenone in patients with myocardial infarction and \"mid-range\" ejection fraction: an analysis from the EPHESUS trial","volume":"42","author":"Ferreira","year":"2019","journal-title":"Clin Cardiol"}],"container-title":["Canadian Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X20311156?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X20311156?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:45:16Z","timestamp":1760107516000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0828282X20311156"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":107,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["S0828282X20311156"],"URL":"https:\/\/doi.org\/10.1016\/j.cjca.2020.11.014","relation":{},"ISSN":["0828-282X"],"issn-type":[{"value":"0828-282X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"How Diabetes and Heart Failure Modulate Each Other and Condition Management","name":"articletitle","label":"Article Title"},{"value":"Canadian Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cjca.2020.11.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}